New Online Ad from Bladder Cancer Advocacy NetworkThere is a need for more options in non-muscle invasive bladder cancer (NMIBC) when BCG fails Bacillus Calmette-Gurin (BCG) has remained the first-line standard of care for more than 40 years
- Though BCG can be initially effective in the first-line treatment of high-risk NMIBC, BCG will fail in more than 40% of patients
- When BCG fails, high-risk patients are more likely to progress to muscle-invasive diseases, bringing them one step closer to life-altering radical cystectomy
"The limited number of patients studied in these [therapeutic] trials, the modest and limited recurrence-free survival with treatment, and the lack of data demonstrating an improvement in progression-free survival illustrate the need for novel agents.
– AUA/SUO Guideline"